Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07494461
Starting soon Observational

Inhibitory Control and Gait Adaptability in Parkinson's Disease

NCT07494461 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2026-04-01
Last updated
2026-03-27

Condition(s) studied

Parkinson Disease (PD)

Study summary

People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles.

The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait adaptability in people with Parkinson's disease. Gait adaptability means the ability to adjust how a person walks in response to changes in the environment, such as stepping over obstacles.

The main questions the study aims to answer are:

* If brain activation related to inhibitory control, measured by EEG, is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
* If behavioral inhibitory control is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?

Participants take part in one study visit. During this visit, participants complete simple thinking tests, have their brain activity recorded using EEG, and perform walking tasks that include stepping over obstacles.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * A clinical diagnosis of idiopathic Parkinson's disease; * Stable use of prescribed antiparkinsonian medication for at least two weeks; * Modified Hoehn and Yahr stage I to III; * Age between 18 and 80 years; * Ability to ambulate independently for at least 30 meters without assistive devices; * A Mini-Mental State Examination (MMSE) score of ≥ 24; * Corrected vision and hearing sufficient to effectively receive external stimuli Exclusion Criteria: * The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study; * The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures; * A history of brain surgery, such as deep brain stimulation (DBS)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
National Yang Ming Chiao Tung University Taipei Taiwan
National Yang Ming Chiao Tung University Taipei Taiwan

More National Yang Ming Chiao Tung University trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07494461 on ClinicalTrials.gov ↗ ← All trials in Taiwan